PET/MR in Breast Cancer.
暂无分享,去创建一个
Bénédicte M A Delattre | Osman Ratib | Raymond Miralbell | Vincent Vinh-Hung | Diomidis Botsikas | O. Ratib | B. Delattre | R. Miralbell | V. Vinh-Hung | O. Rager | Olivier Rager | Claire Tabouret-Viaud | Ismini Mainta | Gaël Amzalag | C. Tabouret-Viaud | G. Amzalag | Diomidis Botsikas | I. Mainta
[1] Nicolas Aide,et al. Staging the axilla in breast cancer patients with 18F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems? , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[2] D. Plewes,et al. Systematic Review: Using Magnetic Resonance Imaging to Screen Women at High Risk for Breast Cancer , 2008, Annals of Internal Medicine.
[3] H. Tsuda,et al. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer , 2008, BMC Cancer.
[4] Daniel B Kopans,et al. Physiologic Changes in Breast Magnetic Resonance Imaging during the Menstrual Cycle: Perfusion Imaging, Signal Enhancement, and Influence of the T1 Relaxation Time of Breast Tissue , 2005, The breast journal.
[5] Heoung Keun Kang,et al. FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations. , 2007, Radiographics : a review publication of the Radiological Society of North America, Inc.
[6] K. Någren,et al. Uptake of 11C-methionine in breast cancer studied by PET. An association with the size of S-phase fraction. , 1991, British Journal of Cancer.
[7] Les Irwig,et al. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. , 2013, Journal of the National Cancer Institute.
[8] G. V. von Schulthess,et al. Value of Retrospective Fusion of PET and MR Images in Detection of Hepatic Metastases: Comparison with 18F-FDG PET/CT and Gd-EOB-DTPA–Enhanced MRI , 2010, Journal of Nuclear Medicine.
[9] J. Parry,et al. MicroPET Imaging of Breast Cancer Using Radiolabeled Bombesin Analogs Targeting the Gastrin-releasing Peptide Receptor , 2006, Breast Cancer Research and Treatment.
[10] M. Sütterlin,et al. [Whole-body MRI in preoperative diagnostics of breast cancer--a comparison with [corrected] staging methods according to the S 3 guidelines]. , 2011, RöFo. Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren (Print).
[11] C. Kuhl,et al. MRI-Based Attenuation Correction for Hybrid PET/MRI Systems: A 4-Class Tissue Segmentation Technique Using a Combined Ultrashort-Echo-Time/Dixon MRI Sequence , 2012, The Journal of Nuclear Medicine.
[12] A. Alavi,et al. Comparison of triple‐negative and estrogen receptor‐positive/progesterone receptor‐positive/HER2‐negative breast carcinoma using quantitative fluorine‐18 fluorodeoxyglucose/positron emission tomography imaging parameters , 2008, Cancer.
[13] V. Seshan,et al. Feasibility and Predictability of Perioperative PET and Estrogen Receptor Ligand in Patients with Invasive Breast Cancer , 2013, The Journal of Nuclear Medicine.
[14] L. Galuska,et al. The value of 18-FDG PET/CT in early-stage breast cancer compared to traditional diagnostic modalities with an emphasis on changes in disease stage designation and treatment plan. , 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[15] V. Kapoor,et al. An introduction to PET-CT imaging. , 2004, Radiographics : a review publication of the Radiological Society of North America, Inc.
[16] R. A. Valdés Olmos,et al. Molecular Imaging in Breast Cancer: From Whole-Body PET/CT to Dedicated Breast PET , 2012, Journal of oncology.
[17] Handel E. Reynolds,et al. ACR Appropriateness Criteria® stage I breast carcinoma. , 2012, Journal of the American College of Radiology : JACR.
[18] Andrea Soricelli,et al. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues. , 2014, European journal of radiology.
[19] D. Groheux,et al. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. , 2008, International journal of radiation oncology, biology, physics.
[20] Kenneth G A Gilhuijs,et al. Current clinical indications for magnetic resonance imaging of the breast , 2014, Journal of surgical oncology.
[21] Evelyn Wenkel,et al. Toward simultaneous PET/MR breast imaging: systematic evaluation and integration of a radiofrequency breast coil. , 2013, Medical physics.
[22] Tomio Inoue,et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[23] C. Boetes,et al. # The Author(s) 2008 , 2007 .
[24] Torsten Mattfeldt,et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[25] H. Tsuda,et al. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study , 2011, Breast cancer.
[26] D. Groheux,et al. Performance of FDG PET/CT in the clinical management of breast cancer. , 2013, Radiology.
[27] David A Mankoff,et al. ACR Appropriateness Criteria Breast Cancer Screening. , 2013, Journal of the American College of Radiology : JACR.
[28] Georg Schramm,et al. Influence and Compensation of Truncation Artifacts in MR-Based Attenuation Correction in PET/MR , 2013, IEEE Transactions on Medical Imaging.
[29] E. Rutgers,et al. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[30] C. Mader,et al. Discrimination and anatomical mapping of PET-positive lesions: comparison of CT attenuation-corrected PET images with coregistered MR and CT images in the abdomen , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[31] K. Yoo,et al. Postmenopausal obesity as a breast cancer risk factor according to estrogen and progesterone receptor status (Japan). , 2001, Cancer letters.
[32] B. Ljung,et al. Breast cancer version 3.2014. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.
[33] I D Wilkinson,et al. Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: A systematic review and meta-analysis. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[34] Axel Haase,et al. A 16-channel MR coil for simultaneous PET/MR imaging in breast cancer , 2015, European Radiology.
[35] H. Kaida,et al. Glucose transporter expression of intraductal papilloma of the breast detected by fluorodeoxyglucose positron emission tomography , 2011, Japanese Journal of Radiology.
[36] David A Mankoff,et al. Evolving role of positron emission tomography in breast cancer imaging. , 2005, Seminars in nuclear medicine.
[37] M. Schwaiger,et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] Roberto Orecchia,et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. , 2010, European journal of cancer.
[39] H. Linden,et al. Novel methods and tracers for breast cancer imaging. , 2013, Seminars in nuclear medicine.
[40] S. Schoenberg,et al. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. , 2008, European journal of radiology.
[41] W. Yang,et al. False-positive lesions mimicking breast cancer on FDG PET and PET/CT. , 2012, AJR. American journal of roentgenology.
[42] P. Drew,et al. Multicentre randomised controlled trial examining the cost-effectiveness of contrast-enhanced high field magnetic resonance imaging in women with primary breast cancer scheduled for wide local excision (COMICE). , 2010, Health Technology Assessment.
[43] Rebecca S Lewis,et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. , 2004, Radiology.
[44] C. Binkert,et al. Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma , 2010, Skeletal Radiology.
[45] P. Neven,et al. Additional Value of PET–CT in Staging of Clinical Stage IIB and III Breast Cancer , 2010, The breast journal.
[46] E. Conant,et al. The impact of FDG PET in the staging of breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] F. Cardoso,et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[48] S. van Esser,et al. Preoperative MRI and surgical management in patients with nonpalpable breast cancer: the MONET - randomised controlled trial. , 2011, European journal of cancer.
[49] K. Hede. Preoperative MRI in breast cancer grows contentious. , 2009, Journal of the National Cancer Institute.
[50] A. Drzezga,et al. First Clinical Experience with Integrated Whole-Body PET/MR: Comparison to PET/CT in Patients with Oncologic Diagnoses , 2012, The Journal of Nuclear Medicine.
[51] G. V. von Schulthess,et al. Whole-body nonenhanced PET/MR versus PET/CT in the staging and restaging of cancers: preliminary observations. , 2014, Radiology.
[52] J L Sunshine,et al. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. , 1993, Radiology.
[53] Handel E. Reynolds,et al. ACR appropriateness criteria palpable breast masses. , 2013, Journal of the American College of Radiology : JACR.
[54] H. Alkadhi,et al. Detection Rate, Location, and Size of Pulmonary Nodules in Trimodality PET/CT-MR: Comparison of Low-Dose CT and Dixon-Based MR Imaging , 2013, Investigative radiology.
[55] E. Mittra,et al. (18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients. , 2014, Radiology.
[56] Simulation and evaluation of a high resolution VIP PEM system with a dedicated LM-OSEM algorithm. , 2014, Journal of instrumentation : an IOP and SISSA journal.
[57] R. Sadeghi,et al. Diagnostic value of 99mTc-bombesin scintigraphy for differentiation of malignant from benign breast lesions , 2014, Nuclear medicine communications.
[58] G. V. von Schulthess,et al. PET/CT versus body coil PET/MRI: how low can you go? , 2013, Insights into Imaging.
[59] E. Mittra,et al. Novel Strategy for a Cocktail 18F-Fluoride and 18F-FDG PET/CT Scan for Evaluation of Malignancy: Results of the Pilot-Phase Study , 2009, Journal of Nuclear Medicine.
[60] C. Sirtori,et al. Magnetic Resonance Imaging Visualization of Vulnerable Atherosclerotic Plaques at the Brachiocephalic Artery of Apolipoprotein E Knockout Mice by the Blood-Pool Contrast Agent B22956/1 , 2014, Molecular imaging.
[61] Maximilian F. Reiser,et al. Whole-Body Magnetic Resonance Imaging and Positron Emission Tomography-Computed Tomography in Oncology , 2007, Topics in magnetic resonance imaging : TMRI.
[62] E. Rutgers,et al. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. , 2010, European journal of cancer.
[63] Andrew Hanby,et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial , 2010, The Lancet.
[64] Selin Carkaci,et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings , 2008, Breast Cancer Research and Treatment.
[65] J. Zeuthen,et al. Gastrin releasing peptide GRP(14–27) in human breast cancer cells and in small cell lung cancer , 1991, Breast Cancer Research and Treatment.
[66] Woo Kyung Moon,et al. Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer , 2011, European Radiology.
[67] A. Jena,et al. imultaneous whole-body 18 F-FDG PET-MRI in primary staging of reast cancer : A pilot study , 2014 .
[68] M. A. van den Bosch,et al. Magnetic resonance imaging in breast cancer: A literature review and future perspectives. , 2014, World journal of clinical oncology.
[69] R. Coleman,et al. Recommendations on the Use of 18F-FDG PET in Oncology , 2008, Journal of Nuclear Medicine.
[70] J. Bading,et al. Imaging of Cell Proliferation: Status and Prospects , 2008, Journal of Nuclear Medicine.
[71] M. Plana,et al. Magnetic resonance imaging in the preoperative assessment of patients with primary breast cancer: systematic review of diagnostic accuracy and meta-analysis , 2011, European Radiology.
[72] Thomas J. Smith,et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] Robert Sacré,et al. Breast imaging. Preoperative breast cancer staging: comparison of USPIO-enhanced MR imaging and 18F-fluorodeoxyglucose (FDC) positron emission tomography (PET) imaging for axillary lymph node staging—initial findings , 2006, European Radiology.
[74] C. D'Orsi,et al. ACR Appropriateness Criteria® on nonpalpable mammographic findings (excluding calcifications). , 2010, Journal of the American College of Radiology : JACR.
[75] B. Kimler,et al. Integrated FDG-PET/CT for initial staging of breast cancer , 2007 .
[76] T. Kinoshita,et al. Comparative study of the value of dual tracer PET/CT in evaluating breast cancer , 2012, Cancer science.
[77] J. Biederer,et al. MRI of pulmonary nodules: technique and diagnostic value , 2008, Cancer imaging : the official publication of the International Cancer Imaging Society.
[78] P. L. Jager,et al. Biodistribution of 89Zr‐trastuzumab and PET Imaging of HER2‐Positive Lesions in Patients With Metastatic Breast Cancer , 2010, Clinical pharmacology and therapeutics.
[79] A. Alavi,et al. Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[80] M. I. Rosa,et al. Accuracy of magnetic resonance in suspicious breast lesions: a systematic quantitative review and meta-analysis , 2011, Breast Cancer Research and Treatment.
[81] J. Katzenellenbogen. Designing steroid receptor-based radiotracers to image breast and prostate tumors. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[82] D. Fuster,et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[83] Paul J. van Diest,et al. Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography , 2002 .
[84] B. Kim,et al. Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer , 2012, Annals of Nuclear Medicine.
[85] E. D. de Vries,et al. 111In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment , 2014, Molecular imaging.
[86] D. Belkić,et al. Molecular imaging in the framework of personalized cancer medicine. , 2013, The Israel Medical Association journal : IMAJ.
[87] A. Kjær,et al. Preoperative PET/CT in early-stage breast cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[88] Matthew J Hayat,et al. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. , 2007, The oncologist.
[89] D. Groheux,et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[90] M. J. García-Velloso,et al. Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer , 2009, The British journal of surgery.
[91] Alessandro Giordano,et al. Diagnostic performance of dedicated positron emission mammography using fluorine-18-fluorodeoxyglucose in women with suspicious breast lesions: a meta-analysis. , 2014, Clinical breast cancer.
[92] C. Xie,et al. A new, preoperative, MRI-based scoring system for diagnosing malignant axillary lymph nodes in women evaluated for breast cancer. , 2012, European journal of radiology.
[93] Thomas J. Smith,et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] P Sismondi,et al. Role of MRI (magnetic resonance imaging) versus conventional imaging for breast cancer presurgical staging in young women or with dense breast. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[95] Jingfei Ma. Dixon techniques for water and fat imaging , 2008, Journal of magnetic resonance imaging : JMRI.
[96] C. Zuiani,et al. Magnetic resonance imaging in patients with nipple discharge: should we recommend it? , 2011, European Radiology.
[97] Young-Taek Oh,et al. Can initial diagnostic PET-CT aid to localize tumor bed in breast cancer radiotherapy: feasibility study using deformable image registration , 2013, Radiation oncology.
[98] D. Fuster,et al. PET/CT with [18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancer. , 2012, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[99] C. Kuhl. Current status of breast MR imaging. Part 2. Clinical applications. , 2007, Radiology.
[100] A. Luini,et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[101] Hiroshi Honda,et al. Diagnostic and Prognostic Value of Pretreatment SUV in 18F-FDG/PET in Breast Cancer: Comparison with Apparent Diffusion Coefficient from Diffusion-Weighted MR Imaging , 2014, The Journal of Nuclear Medicine.
[102] Theodoros N. Arvanitis,et al. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. , 2010, Health technology assessment.
[103] S. Ciatto,et al. Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy , 2013, British Journal of Cancer.
[104] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[105] L. Fallowfield,et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[106] C. Geppert,et al. Pulmonary nodules in patients with primary malignancy: comparison of hybrid PET/MR and PET/CT imaging. , 2013, Radiology.
[107] Gerald Q. Maguire,et al. Role of Fusion of Prone FDG‐PET and Magnetic Resonance Imaging of the Breasts in the Evaluation of Breast Cancer , 2010, The breast journal.
[108] O. Schillaci,et al. 99MTC [13LEU] bombesin and a new gamma camera, the imaging probe, are able to guide mammotome breast biopsy. , 2003, Anticancer research.
[109] Xiaoguang Sun,et al. FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis , 2009, Journal of Cancer Research and Clinical Oncology.
[110] Eric C Ford,et al. Comparison of FDG-PET/CT and CT for delineation of lumpectomy cavity for partial breast irradiation. , 2008, International journal of radiation oncology, biology, physics.
[111] Les Irwig,et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[112] Eric O. Aboagye,et al. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[113] N Houssami,et al. Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. , 2012, Breast.
[114] H. Redmond,et al. Use of Magnetic Resonance Imaging in Detection of Breast Cancer Recurrence: A Systematic Review , 2012, Annals of surgical oncology.
[115] E. Imhoff,et al. Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer , 2004, European Radiology.
[116] M. Greco,et al. Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation , 1998, European Journal of Nuclear Medicine.
[117] H. Tsuda,et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. , 2008, Japanese journal of clinical oncology.
[118] C. Gatsonis,et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. , 2007, The New England journal of medicine.
[119] C. Kuhl. The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. , 2007, Radiology.
[120] G. Vlastos,et al. Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[121] Xiaoyuan Chen,et al. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. , 2009, Bioconjugate chemistry.
[122] Patrick Veit-Haibach,et al. Protocol requirements and diagnostic value of PET/MR imaging for liver metastasis detection , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[123] G Lutterbey,et al. Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. , 1997, Radiology.
[124] M. Piccart,et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[125] Jinsun Lee,et al. Selective Sentinel Node Plus Additional Non-Sentinel Node Biopsy Based on an FDG-PET/CT Scan in Early Breast Cancer Patients: Single Institutional Experience , 2009, World Journal of Surgery.
[126] A. Alavi,et al. Clinicopathologic factors associated with false negative FDG–PET in primary breast cancer , 2006, Breast Cancer Research and Treatment.